PATENT CLAIM ANALYSIS

Application Number: 16054728
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["544", "343000"]

Abstract:
This invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT 2A  receptor, serotonin transporter (SERT) and/or pathways involving dopamine D 1 /D 2  receptor signaling systems, and/or the treatment of residual symptoms.

Claim (Index 14):
The method according to  claim 12 , wherein said disorder is one or more disorders associated with dementia, selected from disorders associated with mild cognition impairment and dementing illnesses including senile dementia, Alzheimer's disease, Pick's disease, fronto-temporal dementia, parasupranuclear palsy, dementia with Lewy bodies, vascular dementia, Huntington's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, Down syndrome, elderly depression, Wernicke-Korsakoff s syndrome, cortico-basal degenerations and prion disease, autism, and attention deficit hyperactivity disorder.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 96.0
- Lexical Diversity: 1.29091
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15301895', '16088397', '15301912', '14394467', '15629481']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8083423235101636
- 35 USC 102 Novelty (BERT): 0.5551960849945841
- Combined Prediction Score: 0.7830276996586055
- Mean Citation Score: 377.4376160000001
- Max Citation Score: 431.4497
- Similarity Product: 376.0914069759072

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test